Patents by Inventor Satoshi Sasamura

Satoshi Sasamura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9969709
    Abstract: [Problem] To provide a compound which is useful as an agent for preventing and/or treating kidney diseases. [Means for Solution] The present inventors have studied compounds having a trypsin inhibitory activity, and have confirmed that a guanidinobenzoic acid ester compound has a trypsin inhibitory activity, thereby completing the present invention. The guanidinobenzoic acid ester compound of the present invention can be used as an agent for preventing and/or treating kidney diseases (for example, chronic kidney disease, acute glomerulonephritis, acute kidney injury, and the like) as an agent which will substitute low-protein diet therapy, and/or as an agent for preventing and/or treating trypsin-related diseases (for example, chronic pancreatitis, gastroesophageal reflux disease, hepatic encephalopathy, influenza, and the like).
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 15, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jiro Fujiyasu, Toru Asano, Susumu Yamaki, Osamu Kaneko, Yuka Koike, Tomoyoshi Imaizumi, Yasuharu Urano, Tomohki Satou, Satoshi Sasamura
  • Publication number: 20160031847
    Abstract: [Problem]To provide a compound which is useful as an agent for preventing and/or treating kidney diseases. [Means for Solution]The present inventors have studied compounds having a trypsin inhibitory activity, and have confirmed that a guanidinobenzoic acid ester compound has a trypsin inhibitory activity, thereby completing the present invention. The guanidinobenzoic acid ester compound of the present invention can be used as an agent for preventing and/or treating kidney diseases (for example, chronic kidney disease, acute glomerulonephritis, acute kidney injury, and the like) as an agent which will substitute low-protein diet therapy, and/or as an agent for preventing and/or treating trypsin-related diseases (for example, chronic pancreatitis, gastroesophageal reflux disease, hepatic encephalopathy, influenza, and the like).
    Type: Application
    Filed: March 13, 2014
    Publication date: February 4, 2016
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Jiro FUJIYASU, Toru ASANO, Susumu YAMAKI, Osamu KANEKO, Yuka KOIKE, Tomoyoshi IMAIZUMI, Yasuharu URANO, Tomohki SATOU, Satoshi SASAMURA
  • Patent number: 9199927
    Abstract: [Problem] Provided is a compound which is useful as an agent for preventing and/or treating renal diseases. [Means for Solution] The present inventors have conducted extensive studies on compounds having a trypsin inhibitory action, and as a result, they have found that a guanidinobenzoic acid compound has a trypsin inhibitory action, thereby completing the present invention. The guanidinobenzoic acid compound of the present invention can be used as an agent for preventing and/or treating renal disease as an agent which will substitute low-protein diet therapy, and an agent for preventing and/or treating trypsin-related diseases, for example, pancreatitis, gastroesophageal reflux disease, hepatic encephalopathy, influenza, and the like.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: December 1, 2015
    Assignee: Astellas Pharma Inc.
    Inventors: Jiro Fujiyasu, Kazuhiko Ohne, Susumu Yamaki, Tomoyoshi Imaizumi, Takeshi Hondo, Keisuke Matsuura, Tomohki Satou, Satoshi Sasamura
  • Publication number: 20140378459
    Abstract: [Problem] Provided is a compound which is useful as an agent for preventing and/or treating renal diseases. [Means for Solution] The present inventors have conducted extensive studies on compounds having a trypsin inhibitory action, and as a result, they have found that a guanidinobenzoic acid compound has a trypsin inhibitory action, thereby completing the present invention. The guanidinobenzoic acid compound of the present invention can be used as an agent for preventing and/or treating renal disease as an agent which will substitute low-protein diet therapy, and an agent for preventing and/or treating trypsin-related diseases, for example, pancreatitis, gastroesophageal reflux disease, hepatic encephalopathy, influenza, and the like.
    Type: Application
    Filed: September 14, 2012
    Publication date: December 25, 2014
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Jiro Fujiyasu, Kazuhiko Ohne, Susumu Yamaki, Tomoyoshi Imaizumi, Takeshi Hondo, Keisuke Matsuura, Tomohki Satou, Satoshi Sasamura
  • Publication number: 20110105420
    Abstract: [Object] Disclosed is a compound useful as an active ingredient for a pharmaceutical composition having an ?-amylase inhibitory activity, particularly a pharmaceutical composition for the treatment of diabetes. [Solution] An investigation has been made on a compound having an ?-amylase inhibitory activity among the compounds produced by Streptomyces sp. strain 6982, which is a actinomycetes belonging to the genus Streptomyces, and it was confirmed that an aminosugar compound has an ?-amylase inhibitory activity, thus completing the invention. The aminosugar compound of the present invention has an ?-amylase-inhibitory activity, and therefore can be used as a prophylactic or therapeutic agent for diabetes, obesity, NASH (non-alcoholic steatohepatitis), particularly as an ameliorating agent for postprandial blood glucose elevation.
    Type: Application
    Filed: April 9, 2009
    Publication date: May 5, 2011
    Applicant: Astellas Pharma Inc.
    Inventors: Satoshi Sasamura, Hiromi Sasamura, Shinya Nishiwaki
  • Patent number: 7696167
    Abstract: A cyclic peptide compound of the following general formula (I): Wherein R1, R2 and R3 are defined in the description, or a salt thereof. The compound (I) is useful for the prophylactic and/or therapeutic treatment of hepatitis C.
    Type: Grant
    Filed: November 21, 2005
    Date of Patent: April 13, 2010
    Assignee: Astellas Pharma Inc.
    Inventors: Motoo Kobayashi, Satoshi Sasamura, Hideyuki Muramatsu, Yasuhisa Tsurumi, Shigehiro Takase, Kazuki Okada
  • Publication number: 20080214447
    Abstract: A cyclic peptide compound of the following general formula (I): Wherein R1, R2 and R3 are defined in the description, or a salt thereof. The compound (I) is useful for the prophylactic and/or therapeutic treatment of hepatitis C.
    Type: Application
    Filed: November 21, 2005
    Publication date: September 4, 2008
    Applicant: Astellas Pharma Inc.
    Inventors: Motoo Kobayashi, Satoshi Sasamura, Hideyuki Muramatsu, Yasuhisa Tsurumi, Shigehiro Takase, Kazuki Okada